Mildly elevated plasma homocysteine levels are an independent risk factor for atherothrombotic vascular disease in the coronary, cerebrovascular, and peripheral arterial circulation. Endothelial dysfunction as manifested by impaired endothelium-dependent regulation of vascular tone and blood ow, by increased recruitment and adhesion of circulating in ammatory cells to the endothelium, and by a loss of endothelial cell antithrombotic function contributes to the vascular disorders linked to hyperhomocysteinemia. Increased vascular oxidant stress through imbalanced thiol redox status and inhibition of important antioxidant enzymes by homocysteine results in decreased bioavailability of the endothelium-derived signaling molecule nitric oxide via oxidative inactivation. This plays a central role in the molecular mechanisms underlying the effects of homocysteine on endothelial function. Supplementation of folic acid and vitamin B 1 2 has been demonstrated to be ef cient in lowering mildly elevated plasma homocysteine levels and in reversing homocysteine-induced impairment of endothelium-dependent vasoreactivity. Results from ongoing intervention trials will determine whether homocysteine-lowering therapies contribute to the prevention and reduction of atherothrombotic vascular disease and may thereby provide support for the causal relationship between hyperhomocysteinemia and atherothrombosis. initial classi cation for several types of hyperhomocysteinemia in humans in relation to fasting total plasma homocysteine concentrations, mild or -synonymously used -moderate hyperhomocysteinemia refers to plasma levels between 12 and 30 mmol/l, intermediate hyperhomocysteinemia to levels between 31 and 100 mmol/l, and severe hyperhomocysteinemia to concentrations .100 mmol/l, respectively. 5 ,6 The purpose of this article is to review recent evidence for the impact of mildly elevated homocysteine levels on endothelial function, recent pathobiological concepts about the development of homocysteine-induced endothelial dysfunction, and possible therapeutic options.
Introduction
The healthy endothelium plays a central role in cardiovascular control. 1 Its complex endocrine and paracrine functions affect vasoregulation, smooth muscle cell proliferation, platelet aggregation, monocyte and leukocyte recruitment and adhesion, and thrombosis, all of which are key features in the pathogenesis and progression of atherothrombosis. 2 Functionally intact endothelium exerts potent anti-atherothrombotic effects. In contrast, endothelial dysfunction plays a crucial role in the pathogenesis of atherothrombotic vascular disease, both as a target and as a mediator of the disease process. 3 ,4 Elevated plasma levels of the sulfur-containing amino acid homocysteine (hyperhomocysteinemia) have been established as a vascular risk factor during the last two decades. Endothelial dysfunction plays a crucial role in homocysteine-induced vascular pathobiology.
There is no consensus on what levels constitute hyperhomocysteinemia at the present time. Recent data show that an increased risk for atherosclerotic vascular disease seems to be associated with fasting homocysteine levels above 12 mmol/l 5 (see the section 'Mildly elevated plasma levels of homocysteine are an independent risk factor for atherothrombotic vascular disease'). In slight modi cation of the Mildly elevated plasma levels of homocysteine are an independent risk factor for atherothrombotic vascular disease As early as 1969, clinical studies in children with rare inborn errors of homocysteine metabolism that lead to markedly elevated plasma homocysteine levels up to 30 times the normal range, revealed the importance of severe hyperhomocysteinemia in the development of premature atherosclerosis and thromboembolism. 7 -9 Based on these observations it was proposed, rst by McCully, 7 that even mildly elevated plasma homocysteine levels, as frequently found in the general population, may play a role in the etiology of vascular diseases.
Since the formulation of the initial hypothesis by McCully, a great number of retrospective case-control studies and prospective nested case-control studies nearly uniformly established the link between mild hyperhomocysteinemia and coronary artery disease, cerebrovascular disease, and peripheral vascular disease. Mild hyperhomocysteinemia appears to be an independent risk factor for arterial vascular disease as this relationship persists after statistical adjustment for conventional risk factors. A metaanalysis by Boushey and colleagues 1 0 using data from 27 studies published before 1995 indicated that a 5 mmol/l increase in plasma homocysteine above median levels of 10 mmol/l is associated with a signi cant and graded increase in the risk of coronary artery disease (odds ratio 1.6 [95% con dence interval (CI): 1.4 to 1.7]), cerebrovascular disease (odds ratio 1.5 [95% CI: 1.3 to 1.9]), and peripheral vascular disease (odds ratio 6.8 [95% CI: 2.9 to 15.8] ). This analysis also documented that a 5 mmol/l increase in plasma homocysteine is equivalent to a 0.5 mmol/l (20 mg/dl) increase in plasma cholesterol in increasing the risk for myocardial infarction. In all, 10% of the population's coronary artery disease risk appears attributable to plasma homocysteine levels. From data of a recent case-control study conducted in nine European centers it was estimated that the cardiovascular risk associated with elevated homocysteine levels detected both under basal conditions (.12 mmol/l) and after an oral methionine challenge (net increase .27 mmol/l over basal levels or absolute increase .38 mmol/l) is comparable to the risk associated with hyperlipidemia or smoking, but somewhat lower than that of hypertension. 5 Prospective cohort studies, which are accepted as providing the most rigorous evidence, have, however, yielded some inconclusive results. Most of the prospective studies have provided evidence for mild hyperhomocysteinemia as a major risk factor for atherothrombotic vascular disease after adjustment for conventional risk factors, 1 1 -2 3 although some studies have not. 2 4 -2 9 These con icting results might be partly explained by the sample size and the different ethnic background and lifestyle of the speci c study's participants. This latter issue appears to be especially important as a source of potential bias owing to multivitamin use by study subjects. For example, the Atherosclerosis Risk in Community Trial, the largest prospective trial with a negative outcome, did not provide detailed information about vitamin supplementation as a potential confounding variable. 2 6 -2 8 Nevertheless, the reasons for the variable results are unknown. Several arguments, however, weigh in favor of the positive studies: (a) nearly all of the retrospective casecontrol studies show a clear-cut association between hyperhomocysteinemia and atherothrombosis; (b) the magnitude of cardiovascular risk correlates with plasma homocysteine levels in many studies; 1 7 ,2 1 ,2 2 ,3 0 ,3 1 (c) several meta-analyses of the retrospective case-control and of the prospective population-based studies showed similar, consistent results favoring hyperhomocysteinemia as a vascular risk factor; 1 0 ,2 2 ,3 2 -3 5 (d) several studies documented an association between mortality in patients with pre-existing coronary or peripheral vascular disease and plasma homocysteine levels independent of traditional risk factors, 1 7 ,3 6 -4 1 or with cerebrovascular events in patients with signi cant stenosis of the carotid artery, 4 2 suggesting that homocysteine may promote acute thrombotic events leading to cardiac death or stroke; (e) plasma homocysteine levels are related to the extent of atherosclerosis in coronary and peripheral arteries 3 and to greater carotid artery intimal-medial wall thickness in cross-sectional studies of subjects with subclinical vascular disease; 4 7 -4 9 and, nally, (f) mildly elevated plasma homocysteine levels induce endothelial vascular dysfunction, a key event in the pathogenesis of atherothrombosis, and lowering of plasma homocysteine levels may have a favorable effect on vascular function. Despite the strong evidence for elevated homocysteine levels as a cardiovascular risk factor, it is not known whether lowering homocysteine levels reduces cardiovascular morbidity and mortality. Several multicenter, randomized, placebo-controlled trials are under way and will provide useful answers within the next few years.
Vascular pathobiology in hyperhomocysteinemia
The pathobiological mechanisms leading to the atherogenic propensity associated with hyperhomocysteinemia are not completely understood as yet. Experimental evidence suggests that hyperhomocysteinemia leads to endothelial dysfunction and injury resulting in decreased vasodilatory capacity, activation of circulating leukocytes and platelets, activation of prothrombotic and inhibition of brinolytic mechanisms, and stimulation of vascular smooth muscle cell proliferation ( Figure 1 ). All these effects support the development or progression of atherosclerotic lesions and thrombus formation.
Endothelial dysfunction as an initial step in atherosclerosis
Endothelial dysfunction as characterized by an imbalance between vasorelaxing and vasocontracting substances, between procoagulant and anticoagulant factors, between proin ammatory and anti-in ammatory mediators, and between inhibitors and promotors of vascular cell growth, is an early and persistent vascular abnormality in the evolution of atherothrombotic disease. The presence of atherosclerotic lesions is associated with endothelial dysfunction manifested as impaired endothelium-dependent regulation of vascular tone. 5 0 - 5 3 In patients with atherosclerotic risk factors, impaired endothelial vasodilator function is notable early in the process of atherogenesis, even prior to the development of frank atherosclerotic lesions. Its extent is related to the intensity and duration of risk factor exposure, and treatment of risk factors results in reversal or attenuation of endothelial dysfunction. 3 ,4 , 5 4 These observations suggest that the endothelium is both a target and a mediator of atherothrombosis. Endothelial vasodilator function may therefore serve as an index integrating the overall stress imposed by vascular risk factors. Indeed, clinical studies have demonstrated that endothelial vasodilator dysfunction is a predictive marker for the future development of coronary artery disease, 5 4 and is associated with a worse prognosis in the setting of existing coronary artery disease predicting coronary disease progression and cardiovascular event rate. 5 5 ,5 6 These ndings underscore the central role of the endothelium in vascular function and its regulation. Impairment of endothelium-dependent vasomotor responses is one indicator of endothelial dysfunction indicative of a reduction in the bioavailability of the endotheliumderived signaling molecule nitric oxide. 5 7 ,5 8 Nitric oxide is This may be caused either by increased oxidative inactivation of nitric oxide by oxygen-derived free radicals that are formed during the auto-oxidation of homocysteine and/or accumulate as a consequence of homocysteine-mediated inhibition of antioxidant enzymes, or by increased endothelial synthesis of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. Decreased bioavailable nitric oxide together with a decrease in the endothelial synthesis of prostacyclin promotes platelet activation and aggregation. Elevated homocysteine levels induce the expression of several chemokines and adhesion molecules by endothelial cells that lead to increased recruitment and adhesion of circulating in ammatory cells. This may be caused by decreased bioavailable nitric oxide and/or increased vascular oxidant stress leading to increased activation of the redox-sensitive transcription factor NF-kB that may mediate the in ammatory response. Homocysteine may further promote thrombosis by activating endothelium-dependent prothrombotic mechanisms, such as the expression of tissue factor, or the activity of factor Va, and by inhibiting antithrombotic and brinolytic mechanisms.
released from endothelial cells in response to increased shear stress 5 9 and certain biochemical stimuli. 6 0 Nitric oxide may function as an endogenous anti-atherogenic molecule by maintaining low arterial tone at rest, inhibiting leukocyte-endothelial interactions, attenuating platelet activation, and inhibiting smooth muscle cell proliferation. 6 1 A reduction in nitric oxide synthesis and/or activity leading to insuf cient biological nitric oxide availability may therefore contribute to the initiation and progression of atherosclerosis.
Decreased nitric oxide bioavailability may re ect an absolute de cit of nitric oxide, impaired availability of bioactive nitric oxide or enhanced nitric oxide inactivation. Decreased nitric oxide synthesis may be due to decreased expression or activity of endothelial nitric oxide synthase, alterations of membrane receptors in the arterial wall that interact with biochemical or physiological stimuli to induce nitric oxide synthesis, decreased availability or af nity of the substrate l-arginine and cofactors, especially tetrahydrobiopterin, for nitric oxide synthase, and elevated levels of endogenous inhibitors of nitric oxide synthase. Impaired bioavailability and bioactivity of nitric oxide may be due to enhanced degradation by increased free radicals and/or oxidation-sensitive mechanisms, impaired nitric oxide diffusion from the endothelium to vascular smooth muscle cells followed by decreased sensitivity to its vasodilator action, and impaired interaction of nitric oxide with guanylate cyclase resulting in decreased cyclic GMP production. 6 1 -6 6 As outlined below, an increase in reactive oxygen species leading to inactivation of nitric oxide and/or an 
Impaired endothelium-dependent vasodilatation as an indicator of endothelial dysfunction in mild hyperhomocysteinemia
Animal models of mild hyperhomocysteinemia, induced by vitamin-de cient and methionine-enriched diets in cynomolgus monkeys 6 7 or rats, 6 8 ,6 9 by heterozygous disruption of the cystathionine b-synthase gene in mice (CBS ( -/+) mice), 7 0 -7 2 or the combination of genetic and dietary approaches, 7 3 showed an impairment of endotheliumdependent vasoreactivity and regulation of blood ow but normal endothelium-independent vasodilatation. Healthy humans with either acutely elevated plasma homocysteine levels following an oral methionine challenge 7 4 -8 4 or with chronic, mild hyperhomocysteinemia 8 5 -8 7 also showed impaired endothelium-dependent vasodilator function, but preserved endothelium-independent vasodilator responses.
Homocysteine, and not methionine or vitamin de ciencies, appears to be responsible for these adverse vascular effects. Mice with a genetic defect in homocysteine transulfuration have mild hyperhomocysteinemia of 1.5-1.8-fold the level in wildtype mice, but have normal plasma methionine levels and are provided a chow that yields normal B-vitamin levels. 7 0 -7 2 Thus, a mild increase in homocysteine alone is suf cient to induce endothelial dysfunction. Impaired endothelial function in humans can be induced by an oral methionine as well as by an oral homocysteine challenge; the latter does not lead to increased plasma levels of methionine. 8 2 ,8 3 Further analyses of different homocysteine species and their time-dependent concentrations in plasma after oral homocysteine or methionine challenges revealed that peak reduction in owmediated dilation coincided with maximal concentrations of reduced homocysteine, but not with free oxidized homocystine, protein-bound oxidized homocystine, or related species, 8 2 suggesting that reduced homocysteine is responsible for vascular dysfunction in vivo.
The observation that homocysteine impairs endotheliumdependent vasodilator function induced by shear stress, acetylcholine or bradykinin but does not impair endotheliumindependent vasodilatation induced by sodium nitroprusside or nitroglycerin indicates that the effects of homocysteine are presumably due to a decrease in bioavailable endogenous nitric oxide. This conclusion is supported by the observation that the accumulation of cyclic guanosine monophosphate, the second messenger of nitric oxidemediated vasodilatation, was decreased in aortas from mildly hyperhomocysteinemic CBS ( -/+) mice compared to their wildtype littermates, 7 0 and that the plasma levels of the nitric oxide-derived end-products nitrite and nitrate were signi cantly lower in hyperhomocysteinemic subjects than in healthy controls. 8 7 In accordance with these in vivo ndings, homocysteine, but not cysteine, has been shown to decrease the production and/or bioactivity of nitric oxide and of S-nitrosothiols by cultured endothelial cells. 7 1 ,8 8 ,8 9 Mechanisms of reduced nitric-oxide bioavailability in hyperhomocysteinemia One of the mechanisms suggested for the adverse effects of homocysteine on endothelial function involves oxidant stress with resulting depletion of bioavailable nitric oxide 9 0 ( Figure 2 ). When added to plasma, homocysteine, like other thiol-containing amino acids, undergoes auto-oxidation, which is accompanied by the generation of reactive oxygen species, such as hydrogen peroxide or superoxide anion. 9 1 An elevation of the oxidation rate of homocysteine and cysteine, expressed as a decreased ratio of reduced to total aminothiols in plasma, has been shown in experimental hyperhomocysteinemia after methionine load 9 2 -9 4 and in hyperhomocysteinemic patients. 9 5 -9 8 In addition to increased formation of reactive oxygen species during auto-oxidation of homocysteine, homocysteine has been shown to inhibit important cellular antioxidant enzymes that may lead to further accumulation of reactive oxygen species. In vitro and in vivo studies have shown that homocysteine, but not other low-molecularweight thiols, decrease the expression and activity of the cellular isoform of glutathione peroxidase (GPx-1). 7 1 ,7 2 ,8 8 ,9 9 -1 0 1 This key enzyme for the cellular defense against oxidant stress uses glutathione to reduce hydrogen peroxide and lipid peroxides to their respective alcohols, 1 0 2 and may also act as a peroxynitrite reductase. 1 0 3 Furthermore, extracellular superoxide dismutase, a secretory glycoprotein with an af nity for heparin-like substances, is present in the circulation in equilibrium between the plasma phase and the glycosaminoglycans on the endothelium, and is the principal enzymatic scavenger of superoxide in the extracellular space. 1 effect is caused by decreased binding of extracellular superoxide dismutase to endothelial cell surfaces by degradation of the endothelial heparan sulfate proteoglycan by homocysteine, 1 0 7 and may result in a loss of the ability to protect the endothelial surface from oxidative stress, although this hypothesis has not yet been proven.
The role of superoxide formation in homocysteineinduced endothelial dysfunction is underscored by the demonstration of greater superoxide production in aortic tissue from mildly hyperhomocysteinemic mice than from wildtype mice 7 0 and from cultured endothelial cells incubated with homocysteine. 1 0 8 Furthermore, scavenging of superoxide anion by either superoxide dismutase or Tiron has been shown to reverse endothelial dysfunction in hyperhomocysteinemic animal models 7 0 ,1 0 9 and in isolated aortic rings incubated with homocysteine. 1 0 8 Superoxide anion can react with nitric oxide to form the highly reactive peroxynitrite, which leads to inactivation of nitric oxide's biological activity. 1 1 0 Peroxynitrite has a short half-life, which makes its detection dif cult in biological systems, 1 1 1 but may react with cellular tyrosine residues to form nitrosated end-products. Immunostaining for one such end-product, 3nitrotyrosine, was positive in aortic tissue from mildly hyperhomocysteinemic CBS ( -/+) mice compared with wildtype mice, 7 0 as was an immunoblot analysis for 3-nitrotyrosine of protein lysates from aortic rings cultured in homocysteine containing media. 1 1 2 These two studies indirectly document increased peroxynitrite formation in hyperhomocysteinemia.
The role for hydrogen peroxide in homocysteine-induced endothelial toxicity in vitro is supported by the nding that catalase was able to inhibit the homocysteine-induced lysis of endothelial cells in the presence of transition metals or ceruloplasmin. 1 1 3 ,1 1 4 More recently, an increase in the uorescence of a hydrogen peroxide-sensitive uorescent probe, 29,79-dichloro uorescein, was observed in cultured endothelial cells 8 9 ,1 1 5 ,1 1 6 and cultured vascular smooth muscle cells exposed to homocysteine. 1 1 7 Hydrogen peroxide decomposes to the toxic oxygen species hydroxyl radical, which is highly reactive and causes lipid peroxidation, and to hydroxide anion, which promotes alkaline tissue damage. Furthermore, elevated levels of lipid peroxides lead to an increase in peroxyl radicals that can inactivate nitric oxide through the formation of lipid peroxynitrites.
The intracellular redox buffer system consisting of reduced glutathione and glutathione disul de together with glutathione reductase and glutathione peroxidase plays a central role in the cellular defense against oxidant stress and has an important role in maintaining endothelial function. This point is underscored by the ndings that nitric oxide synthesis is impaired in glutathione-depleted human endothelial cells and, conversely, bolstering cellular glutathione content with glutathione monoethyl ester results in enhanced nitric oxide production. 1 1 8 Furthermore, mice de cient in cellular glutathione peroxidase have endothelial dysfunction due to increased vascular oxidative stress with resulting reduction in the bioavailability of nitric oxide. 1 1 9 The role of the cellular redox state in homocysteineinduced endothelial dysfunction is emphasized by the observation that treatment of hyperhomocysteinemic CBS ( -/+) mice with the intracellular cysteine donor l-2oxo-4-thiazolidine carboxylate, an agent that increases intracellular levels of reduced glutathione and total thiols and thereby shifts the cellular redox state to a more reduced environment, restores endothelial function. 7 2 The speci c role of cellular glutathione peroxidase in homocysteineinduced endothelial dysfunction is demonstrated by the observations that overexpression of cellular glutathione peroxidase in hyperhomocysteinemic CBS ( -/+) mice restores the normal endothelium-dependent vasodilator response, and that overexpression of cellular glutathione peroxidase in cultured endothelial cells attenuates the homocysteineinduced decrease in nitric oxide release from these cells. 7 1 These ndings demonstrate that increasing the cellular antioxidant capacity by either increasing the concentration of reduced glutathione or overexpression of cellular glutathione peroxidase compensates for the adverse effects of homocysteine on endothelial function, and suggests that the adverse vascular effects of homocysteine are at least partly mediated by oxidative inactivation of nitric oxide. This view is further supported by studies in humans demonstrating that pretreatment with antioxidants prevented endothelial and platelet dysfunction induced in healthy individuals by an oral methionine challenge. 7 Hyperhomocysteinemia-induced oxidant stress not only leads to biological inactivation of nitric oxide but may also lead to lipid peroxidation at the cell surface and direct oxidation of low-density lipoprotein, 9 1 ,1 2 1 ,1 2 2 and may indirectly contribute to oxidative modi cation of low-density lipoprotein mediated by vascular cells in vitro. 9 1 ,1 2 1 -1 2 3 All these events are known to be important in the initial steps of atherothrombosis. In accordance with these in vitro ndings, animals fed a methionine-rich diet leading to hyperhomocysteinemia showed an increase in plasma and in aortic thiobarbituric acid-reactive substances that was related to the development of atherosclerotic Vascular Medicine 2002; 7: 227-239 lesions. 1 1 5 ,1 2 4 ,1 2 5 Mildly hyperhomocysteinemic CBS ( -/+) mice showed increased plasma levels of the isoprostane F 2 a -III, an end-product of the non-enzymatic peroxidation of arachidonic acid. 7 0 An association of elevated plasma homocysteine levels with enhanced in vivo lipid and protein oxidation in humans is suggested by the correlation of plasma homocysteine with plasma F 2 -isoprostanes, 1 2 6 and by increased levels of malondialdehyde, conjugated dienes, and oxidized proteins in hyperhomocysteinemic patients. 1 2 7 A complementary hypothesis that might contribute to the reduced bioavailability of nitric oxide in hyperhomocysteinemia is an elevation of the plasma concentration of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. 1 2 8 Dimethylarginines are likely formed from the degradation of proteins containing methylated arginine residues. 1 2 9 Methylated arginines are either excreted in the urine or metabolized to citrulline by the enzyme dimethylarginine dimethylaminohydrolase. Cynomolgus monkeys fed a methionine-rich, folic aciddepleted diet free of choline, and healthy humans after an oral methionine challenge showed increased plasma levels of asymmetric dimethylarginine that correlated with endothelial dysfunction. 8 1 ,1 3 0 In addition, when endothelial cells or non-vascular cells were exposed to homocysteine or to its precursor methionine, the concentration of asymmetric dimethylarginine in the cell culture medium increased in a dose-and time-dependent fashion, associated with reduced nitric oxide synthesis by endothelial cells. The homocysteine-induced increase in asymmetric dimethylarginine by cells was associated with a reduction in the activity of dimethylarginine dimethylaminohydrolase, the enzyme that degrades asymmetric dimethylarginine. This inhibitory effect of homocysteine appears to be caused either by direct binding and functional interference of the reactive sulfhydryl group of homocysteine with cysteine groups of dimethylarginine dimethylaminohydrolase, as it can be prevented by a thiol antioxidant that protects sulfhydryl groups, and by the reducing agent dithiothreitol, 1 3 1 or by increased oxidant stress under conditions of elevated homocysteine, as it has been previously shown that oxidative stress impairs the activity of dimethylarginine dimethylaminohydrolase and increases dimethylarginine elaboration by endothelial cells. 1 3 2 These observations therefore do not contrast but rather complement the hypothesis that homocysteine may impair nitric oxide bioactivity by oxidative degradation. Furthermore, work from several groups has shown that homocysteine decreases the proliferation rate of cultured vascular endothelial cells and induces programmed cell death in cultured endothelial cells which might contribute to endothelial cell injury in hyperhomocysteinemia. 9 9 ,1 3 3 ,1 3 4 These effects are likely caused by homocysteine-induced endoplasmic reticulum stress. A nding that supports the observation that homocysteine causes a dose-dependent decrease in DNA synthesis and proliferation of endothelial cells 9 9 ,1 3 3 is that homocysteine-induced endoplasmic reticulum stress leads to changes in the expression of several genes, including those that mediate cell growth and differentiation (i.e. GADD45, GADD153, Id-1, cyclin D1, FRA-2). 9 9 Homocysteine-induced apoptosis in endothelial cells 1 3 4 appears to be mediated by activation of the unfolded protein response, a signal transduction pathway activated by the accumulation of unfolded proteins in the lumen of the endoplasmic reticulum. 1 3 4 ,1 3 5
Homocysteine-induced endothelial dysfunction augments the recruitment and adhesion of circulating mononuclear cells to the endothelium
In addition to an impairment of endothelium-dependent vascular reactivity, homocysteine-induced endothelial dysfunction may be manifest as an activation of endothelial cells leading to increased expression of chemokines and adhesion molecules resulting in increased recruitment of circulating in ammatory blood cells and their increased adhesion at the endothelium. All these events are known to play an important role in the pathogenesis of early atherosclerotic lesions and their progression. 1 3 6 Incubation of cultured endothelial cells with homocysteine has been shown to increase the expression of the chemoattractant proteins MCP-1 and IL-8 leading to increased chemotaxis of human peripheral blood monocytes and U937 cells. 1 3 7 Homocysteine has also been shown to stimulate the expression of the MCP-1 receptor (CCR2) in human monocytes, an effect that is possibly mediated by oxygen-derived free radicals. 1 3 8 Mildly hyperhomocysteinemic CBS ( -/+) mice showed increased plasma levels of soluble P-selectin and increased expression of P-selectin on aortic tissue compared to wildtype mice; these effects were reversible with antioxidant therapy. 7 2 In hyperlipidemic apolipoprotein E-null mice that had been made hyperhomocysteinemic by a methionine-enriched diet depleted in B vitamins, hyperhomocysteinemia was associated with increased expression of VCAM-1, tissue factor, RAGE and MMP-9 in aortic sections. 1 3 9 These ndings correlated with increased atherosclerotic lesion area and complexity, pointing out that hyperhomocysteinemia may promote atherosclerotic lesion progression via an enhanced vascular in ammatory response. The mechanisms underlying these observations are not yet clear. Reduced bioavailability of nitric oxide promoting P-selectin expression 7 2 and/or activation of the redox sensitive transcription factor NF-kB regulating VCAM-1, tissue factor and RAGE expression 1 3 9 may be involved in vascular in ammatory response to hyperhomocysteinemia.
Inhibition of endothelial cell thromboresistance by homocysteine
Experimental work from several groups suggests that homocysteine may alter endothelial cell function to promote thrombosis. Homocysteine has been shown to impair the ability of endothelial cells to inhibit platelet aggregation in vitro, likely by reducing nitric oxide bioavailability, 1 4 0 or by decreasing the biosynthesis of prostacyclin, 1 4 1 ,1 4 2 although the latter data are still somewhat controversial. 1 4 3 In addition, exposure of endothelial cells to homocysteine increases tissue factor expression 1 4 4 and the activation of factor V to factor Va, 1 4 5 thus favoring thrombin generation through initiation and propagation of the coagulation cascade. These procoagulant effects of homocysteine may be potentiated by inhibition of endogenous anticoagulants and inhibition of brinolysis by homocysteine. Homocysteine has been shown to inhibit thrombomodulin expression and activity, 1 4 6 ,1 4 7 and thrombomodulin-dependent activation of the anticoagulant protein C by thrombin. 1 4 8 In addition, homocysteine may inhibit inactivation of factor Va by activated protein C through homocysteinylation of the cofactor, 1 4 9 and may reduce the binding of antithrombin III to the endothelial surface through inhibition of heparan sulfate Vascular Medicine 2002; 7: 227-239 expression. 1 5 0 Inhibition of endothelial-dependent brinolysis by homocysteine is suggested by the nding of impaired binding and activity of tissue-type plasminogen activator on the endothelial cell surface. 1 5 1 This effect is mediated by derivatization of the tail domain of annexin II by homocysteine at a cysteine residue, which inhibits tissue-type plasminogen activator binding to the endothelial cell surface. 1 5 2 All these observations suggest that hyperhomocysteinemia promotes thrombosis. However, most of the in vitro studies mentioned above were performed with homocysteine concentrations above pathophysiologically relevant levels, or were reproduced with cysteine, and, thus, could be related to the non-speci c reactivity of the sulfhydryl group of homocysteine. 1 4 0 ,1 4 4 ,1 5 0 Support of the hypothesis that mild hyperhomocysteinemia induces a prothrombotic state in vivo is derived from animal studies and clinical observations. The view that platelet hyper-reactivity occurs in hyperhomocysteinemic states is supported by the nding that dietary folate de ciency in rats induces platelet hyper-reactivity and increases macrophage tissue factor activity, effects that correlate with increases in homocysteine levels. 1 5 3 Plasma homocysteine concentrations induced by methionine challenge in rats correlated with platelet aggregation and increased synthesis of the proaggregant thromboxane A 2 . 1 5 4 Increased thromboxane A 2 synthesis has also been documented in homocystinuric patients. 1 5 5 ,1 5 6 In addition, plasma homocysteine concentrations were found to correlate with plasma brinogen levels in mildly hyperhomocysteinemic patients with coronary heart disease, 4 6 and increased levels of von Willebrand factor were found in mildly hyperhomocysteinemic patients with premature arterial disease 1 5 7 and in healthy individuals after methionine challenge. 1 5 8 Together with a reduction of the antiplatelet effects of nitric oxide by homocysteine, 1 4 0 these further support the view that increased platelet activation and aggregation may be involved in the development of thrombosis in hyperhomocysteinemia.
Promotion of atherosclerosis lesion size by homocysteine
Recent animal studies suggest that homocysteine not only leads to functional vascular changes but, in addition, may promote atherosclerotic lesion development and progression. In two recent studies, apolipoprotein E-de cient mice were fed diets that raised plasma homocysteine levels up to 36-47 mmol/l. 1 3 9 ,1 5 9 Hyperlipidemic apolipoprotein E-null mice spontaneously develop complex atherosclerotic lesions, but when fed a hyperhomocysteinemic diet for 8 weeks or 3 months, respectively, they develop atherosclerotic lesions in the aorta that were of greater size and complexity than those seen in apolipoprotein E-null mice fed normal chows. These two reports are the rst to demonstrate that hyperhomocysteinemia in uences the development of atherosclerosis in a susceptible animal model.
Therapeutic options
Plasma homocysteine levels are strongly and inversely correlated with plasma levels of folic acid and, to a lesser extent, with vitamin B 6 and vitamin B 1 2 levels. 1 6 0 ,1 6 1 Conversely, numerous clinical studies, including 12 randomized and placebo-controlled intervention studies, have uniformly shown that supplementation with these vitamins effectively lowers plasma homocysteine levels. A recently performed meta-analysis of the published controlled clinical trials indicated 1 6 2 that folic acid supplementation reduces homocysteine levels by 25% (95% CI: 23 to 28) with similar effects in a daily dose range of 0.5-5 mg. An additional reduction in plasma homocysteine is produced by vitamin B 1 2 (mean dose 0.5 mg), whereas vitamin B 6 in a mean dose of 16.5 mg did not have any signi cant effect. A comparison of different strategies to increase the folic acid supply to about 600 mg per day showed that the daily consumption of folic acid-forti ed breakfast cereals or the intake of folic acid tablets is more effective than the consumption of folic acid-rich natural food in lowering plasma homocysteine levels. 1 6 3 The reason for this observation is that despite adequate dietary instruction of participants, daily folic acid intake increased to a smaller extent in subjects consuming natural food compared to subjects using folic acid supplements. Unwanted side effects of vitamin supplementation using physiological doses (folic acid up to 10 mg per day, vitamin B 6 up to 100 mg per day) have not been observed thus far; however, folic acid supplementation in subjects who are vitamin B 1 2 -de cient may unmask the adverse effects of this de ciency state. Although vitamin B 1 2 has only a small additional homocysteine-lowering effect, it may be added primarily to avoid the theoretical risk of neuropathy of folic acid therapy in vitamin B 1 2de cient patients, even those with intrinsic factor de ciency or malabsorption states. 1 6 4 -1 6 6 In July 1997, the USA, 1 6 7 and in November 1998, Canada, 1 6 8 began mandatory forti cation of cereal grain our products with folic acid (140 mg per 100 g our in the USA and 150 mg per 100 g our in Canada), primarily intended to reduce the risk of neural-tube defects in newborns. Food forti cation at this level was estimated to provide an additional 70-120 mg of folic acid per day to the diet of young and middle-aged adults. This resulted in a substantial decrease in mean plasma homocysteine levels 1 6 9 -1 7 1 and in the prevalence of hyperhomocysteinemia .13 mmol/l from 18.7% to 9.8% (p , 0.001) in the Framingham Offspring Cohort, representative of the general population. 1 6 9 Patients with renal insuf ciency, however, did not pro t from the food forti cation program in terms of lowering homocysteine levels. 1 7 1 ,1 7 2 Although lowering of plasma homocysteine levels by vitamin supplementation has been shown to be ef cient and safe, conclusive data from randomized and placebo-controlled intervention trials, proving a bene cial effect of vitamin supplementation on morbidity and mortality from atherothrombotic vascular disease, are not yet available. Several prospective intervention trials are currently ongoing in Europe, North America, and Australia that are designed to investigate the effect of vitamin supplementation on clinical endpoints of cardiovascular, cerebrovascular, peripheral arterial occlusive and venous thromboembolic diseases in primary or secondary prevention. More than 60 000 patients will be included in these trials which are likely to have important therapeutic impact, although there is some concern that the trials performed in North America remain adequately powered to test the hypothesis in the era of folic acid forti cation of cereal grains. 1 7 3 There is some uncontrolled evidence from observations in patients with severe hyperhomocysteinemia due to cysta-Vascular Medicine 2002; 7: 227-239 thionine b-synthase de ciency that homocysteine-lowering therapy prevents vascular complications. A study on the natural history of untreated severe hyperhomocysteinemia in 629 patients disclosed that patients beyond the age of 10 years suffer one vascular event per 25 patient-years. 8 A multicenter observational study documented the effects of long-term homocysteine-lowering treatment for severe hyperhomocysteinemia due to cystathionine b-synthase de ciency on vascular outcome. A total of 158 patients with 2822 patient-years of treatment were observed. Treatment with vitamin B 6 alone in vitamin B 6 -responsive patients, or in combination with betaine in vitamin B 6 -nonresponsive patients, resulted in a marked reduction of plasma homocysteine from pretreatment levels that, however, usually remained moderately elevated. There were 17 vascular events in 12 treated patients. Without treatment, 112 vascular events would have been expected, which represents a relative risk for vascular events in treated patients of 0.09 (95% CI: 0.036 to 0.228; p , 0.0001). 1 7 4 These ndings show that treatment regimens designed to lower plasma homocysteine signi cantly reduce cardiovascular risk in severely hyperhomocysteinemic patients due to cystathionine b-synthase de ciency despite imperfect biochemical control.
Some encouraging short-term clinical studies investigated the effect of vitamin supplementation on surrogate markers of vascular disease in patients with mild hyperhomocysteinemia. Plasma levels of von Willebrand factor and soluble thrombomodulin are established biochemical markers of endothelial injury or activation 1 7 5 ,1 7 6 and increased in patients with hyperhomocysteinemia. 1 5 7 Treatment of young patients with peripheral arterial occlusive disease and elevated plasma homocysteine levels with folic acid (5 mg per day) and pyridoxine (250 mg per day) in an uncontrolled, longitudinal study decreased plasma homocysteine levels and signi cantly reduced the plasma levels of von Willebrand factor and thrombomodulin. 1 7 7 An uncontrolled, longitudinal study on the progression of carotid plaque area in patients with no atherosclerotic risk factors except homocysteine levels greater than 14 mmol/l demonstrated that the atherosclerotic plaque area increased in patients with hyperhomocysteinemia at a rate of 0.31 6 0.39 cm 2 /year, but remained stable after initiation of vitamin supplementation (rate of progression -0.05 6 0.25 cm 2 /year; p = 0.02). 1 7 8 In a randomized and placebo-controlled trial among 158 healthy siblings of patients with premature atherothrombotic disease, participants were treated with folic acid and vitamin B 6 for 2 years. Approximately two-thirds of the participants had elevated plasma homocysteine levels at baseline that signi cantly decreased with treatment. Vitamin treatment was associated with a decreased rate of abnormal exercise stress tests (odds ratio 0.40 [95% CI: 0.17 to 0.93]; p = 0.035). 1 7 9 The effect of oral folic acid supplementation in hyperhomocysteinemic subjects on endothelial function as assessed by ow-mediated endothelium-dependent dilation of the brachial artery using high-resolution ultrasound has been investigated in several double-blind, randomized, placebocontrolled crossover trials. Folic acid supplementation (5 mg/day for 6 weeks) compared to placebo lowered total plasma homocysteine levels (8.7 6 2.5 vs 12.1 6 3.6 mmol/l; p = 0.003) and improved arterial endothelial function (increase in diameter + 0.08 6 0.05 mm vs 0.04 6 0.04 mm; p = 0.015) in healthy adults without conventional atherosclerotic risk factors but mildly elevated homocysteine levels at baseline (.13 mmol/l). 1 8 0 These ndings were reproduced by others in similarly designed studies 8 7 ,1 8 1 and also in subjects with acute hyperhomocysteinemia following an oral methionine challenge, 1 8 2 or in patients with existing coronary artery disease and elevated plasma homocysteine levels. 1 8 3 -1 8 6 This effect may be a consequence of increased bioavailable nitric oxide after folic acid supplementation as indicated by improved endothelium-dependent vasodilation but not of endotheliumindependent vasodilation in all cited studies and by an increase in the plasma level of nitric oxide-derived endproducts by folic acid supplementation. 8 7 The improvement of ow-mediated dilation correlates closely with the reduction in free plasma homocysteine, 1 8 4 independent of changes in total or protein-bound homocysteine, folate, and vitamin B 1 2 , 1 8 4 ,1 8 5 supporting the view that reduced homocysteine is the species that is deleterious to the endothelium. Some studies that investigated the effect of vitamin supplementation on endothelial dysfunction in hyperhomocysteinemic subjects, but, however, could not document a positive effect, 1 8 7 -1 8 9 which can partly be explained by insuf cient lowering of plasma homocysteine levels by folic acid in patients with predialysis renal failure (posttreatment homocysteine levels: odds ratio 15.1 [95% CI: 14.1 to 16.2] mmol/l), 1 8 7 use of lower doses of folic acid compared with positive studies (400 mg supplements), 1 8 8 or inadequate sample size. 1 9 0 In addition, recent data suggest that folic acid may improve endothelial function and nitric oxide synthesis by mechanisms independent from its homocysteine-lowering effect. 1 9 1 Recent evidence suggests that 5-methyltetrahydrofolate, the reduced form of dietary folic acid, may bind to a pteridine binding domain in nitric oxide synthases that is similar to the folate-binding site of dihydrofolate reductase. This may facilitate tetrahydrobiopterin's radical-mediated reductive activation of the ferrous heme-O 2 moiety of the enzyme, which is involved in the catalytic formation of nitric oxide, and may thereby increase nitric oxide production. 1 9 2 In conclusion, the studies reviewed here provide evidence that lowering plasma homocysteine levels by B-vitamin supplementation improves endothelial dysfunction as indicated by the reduction of elevated biochemical markers of endothelial injury or activation, and by improvement of endothelium-dependent vasodilator function. These encouraging ndings support the need for large, randomized, controlled trials aimed at investigating the effect of vitamin supplementation on clinical endpoints of vascular disease.
